J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.
UCB, a global biopharmaceutical company, today announced Week 16 data from the BE BOLD trial demonstrating superior ACR50 joint outcomes at Week 16 for BIMZELX® (bimekizumab-bkzx) versus SKYRIZI® ...
Injections deliver liquid medications, fluids, or nutrients directly into a person’s body. Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results